Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management

Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs & aging 2024-09, Vol.41 (9), p.713-724
Hauptverfasser: Tada, Yoshifumi, Maruyama, Akihito, Shirahama, Yuri
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 724
container_issue 9
container_start_page 713
container_title Drugs & aging
container_volume 41
creator Tada, Yoshifumi
Maruyama, Akihito
Shirahama, Yuri
description Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.
doi_str_mv 10.1007/s40266-024-01137-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3087699406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3087699406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</originalsourceid><addsrcrecordid>eNp9kM1O3DAQxy1UVL76AhyqSL1wIDC2EzvuDS0fRQLtga7Um-Ukk1WQ16Ge5MCtr9HX40kw7EKlHjh55PnNf0Y_xg45nHAAfUoFCKVyEEUOnEudqy22y7k2OTfKfHqtIRfC_Nphe0T3AKCE4J_ZjjRgdCnLXba4G3vvn_78pey8J3SE2TwQjlkfsrlvMWZn7eRH-p7NfB_6xvnsEt04RaTjNOGWYaA-lS602a0LbokrDOMB2-6cJ_yyeffZ4vLi5-xHfjO_up6d3eSNFGrM68rUiG0N6KA2BmvdSQHphxuJujSlwqrrlCzrlmOtdCFk26gKtCxQcmjkPjta5z7E4feENNpVTw167wIOE1kJlVbGFKAS-u0_9H6YYkjX2RRVVbzUWidKrKkmDkQRO_sQ-5WLj5aDfZFu19Jtkm5fpduX6K-b6KleYfs-8mY5AXINUGqFJcZ_uz-IfQbehIx-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108815777</pqid></control><display><type>article</type><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</creator><creatorcontrib>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</creatorcontrib><description>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</description><identifier>ISSN: 1170-229X</identifier><identifier>ISSN: 1179-1969</identifier><identifier>EISSN: 1179-1969</identifier><identifier>DOI: 10.1007/s40266-024-01137-6</identifier><identifier>PMID: 39097535</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Arthritis ; Biological products ; Biomarkers ; Case reports ; Clinical outcomes ; Cluster analysis ; Cytokines ; Dehydrogenases ; Fever ; Geriatrics/Gerontology ; Humans ; Immunosuppressive agents ; Inflammation ; Inflammatory diseases ; Internal Medicine ; Laboratories ; Medical diagnosis ; Medical prognosis ; Medical treatment ; Medicine ; Medicine &amp; Public Health ; Mortality ; Older people ; Pharmacology/Toxicology ; Pharmacotherapy ; Pulmonary embolisms ; Review Article ; Still's Disease, Adult-Onset - diagnosis ; Still's Disease, Adult-Onset - drug therapy ; Still's Disease, Adult-Onset - therapy ; Young adults</subject><ispartof>Drugs &amp; aging, 2024-09, Vol.41 (9), p.713-724</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Sep 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</cites><orcidid>0000-0003-0742-831X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40266-024-01137-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40266-024-01137-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39097535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Maruyama, Akihito</creatorcontrib><creatorcontrib>Shirahama, Yuri</creatorcontrib><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><title>Drugs &amp; aging</title><addtitle>Drugs Aging</addtitle><addtitle>Drugs Aging</addtitle><description>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</description><subject>Aged</subject><subject>Arthritis</subject><subject>Biological products</subject><subject>Biomarkers</subject><subject>Case reports</subject><subject>Clinical outcomes</subject><subject>Cluster analysis</subject><subject>Cytokines</subject><subject>Dehydrogenases</subject><subject>Fever</subject><subject>Geriatrics/Gerontology</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Internal Medicine</subject><subject>Laboratories</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mortality</subject><subject>Older people</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Pulmonary embolisms</subject><subject>Review Article</subject><subject>Still's Disease, Adult-Onset - diagnosis</subject><subject>Still's Disease, Adult-Onset - drug therapy</subject><subject>Still's Disease, Adult-Onset - therapy</subject><subject>Young adults</subject><issn>1170-229X</issn><issn>1179-1969</issn><issn>1179-1969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1O3DAQxy1UVL76AhyqSL1wIDC2EzvuDS0fRQLtga7Um-Ukk1WQ16Ge5MCtr9HX40kw7EKlHjh55PnNf0Y_xg45nHAAfUoFCKVyEEUOnEudqy22y7k2OTfKfHqtIRfC_Nphe0T3AKCE4J_ZjjRgdCnLXba4G3vvn_78pey8J3SE2TwQjlkfsrlvMWZn7eRH-p7NfB_6xvnsEt04RaTjNOGWYaA-lS602a0LbokrDOMB2-6cJ_yyeffZ4vLi5-xHfjO_up6d3eSNFGrM68rUiG0N6KA2BmvdSQHphxuJujSlwqrrlCzrlmOtdCFk26gKtCxQcmjkPjta5z7E4feENNpVTw167wIOE1kJlVbGFKAS-u0_9H6YYkjX2RRVVbzUWidKrKkmDkQRO_sQ-5WLj5aDfZFu19Jtkm5fpduX6K-b6KleYfs-8mY5AXINUGqFJcZ_uz-IfQbehIx-</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Tada, Yoshifumi</creator><creator>Maruyama, Akihito</creator><creator>Shirahama, Yuri</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0742-831X</orcidid></search><sort><creationdate>20240901</creationdate><title>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</title><author>Tada, Yoshifumi ; Maruyama, Akihito ; Shirahama, Yuri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-b89beedb0ea0b99eb7f320eed193e75956e8ff635bd1eb67423dc680734e310c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Arthritis</topic><topic>Biological products</topic><topic>Biomarkers</topic><topic>Case reports</topic><topic>Clinical outcomes</topic><topic>Cluster analysis</topic><topic>Cytokines</topic><topic>Dehydrogenases</topic><topic>Fever</topic><topic>Geriatrics/Gerontology</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Internal Medicine</topic><topic>Laboratories</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mortality</topic><topic>Older people</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Pulmonary embolisms</topic><topic>Review Article</topic><topic>Still's Disease, Adult-Onset - diagnosis</topic><topic>Still's Disease, Adult-Onset - drug therapy</topic><topic>Still's Disease, Adult-Onset - therapy</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Maruyama, Akihito</creatorcontrib><creatorcontrib>Shirahama, Yuri</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs &amp; aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tada, Yoshifumi</au><au>Maruyama, Akihito</au><au>Shirahama, Yuri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management</atitle><jtitle>Drugs &amp; aging</jtitle><stitle>Drugs Aging</stitle><addtitle>Drugs Aging</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>41</volume><issue>9</issue><spage>713</spage><epage>724</epage><pages>713-724</pages><issn>1170-229X</issn><issn>1179-1969</issn><eissn>1179-1969</eissn><abstract>Still’s disease (SD) is a rare systemic inflammatory disease that is characterized by high fever, polyarthritis, and an evanescent rash as its main symptoms but that may also be complicated by pleuritis and macrophage activation syndrome (MAS). There has been a recent increase in studies on older-onset SD, which presents with less-typical clinical features, such as sore throat, skin lesions, and splenomegaly, but more complications including pleuritis and disseminated intravascular coagulation. Several reports have shown higher levels of inflammatory markers, including serum ferritin, and poorer outcomes in terms of survival and drug-free remission in older patients. In addition, caution is needed when diagnosing SD in older patients because of the increased incidence of differential diagnoses such as infectious diseases, malignancies, and inflammatory diseases. Prognosis is poor in older patients, and treatment-associated infections and severe complications such as MAS are the main cause of mortality. The use of biologics and treatment response may not differ greatly between older and younger patients. Although the data are limited, anti-IL-1 and anti-IL-6 agents may control SD in these patients with careful use and adequate infection prevention. Recent studies that classified adult-onset SD by cluster analysis or latent class analysis showed that older patients form a unique cluster of SD, indicating the need for clinicians to pay more attention to the diagnosis and management of SD in older patients.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39097535</pmid><doi>10.1007/s40266-024-01137-6</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0742-831X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1170-229X
ispartof Drugs & aging, 2024-09, Vol.41 (9), p.713-724
issn 1170-229X
1179-1969
1179-1969
language eng
recordid cdi_proquest_miscellaneous_3087699406
source MEDLINE; SpringerLink Journals
subjects Aged
Arthritis
Biological products
Biomarkers
Case reports
Clinical outcomes
Cluster analysis
Cytokines
Dehydrogenases
Fever
Geriatrics/Gerontology
Humans
Immunosuppressive agents
Inflammation
Inflammatory diseases
Internal Medicine
Laboratories
Medical diagnosis
Medical prognosis
Medical treatment
Medicine
Medicine & Public Health
Mortality
Older people
Pharmacology/Toxicology
Pharmacotherapy
Pulmonary embolisms
Review Article
Still's Disease, Adult-Onset - diagnosis
Still's Disease, Adult-Onset - drug therapy
Still's Disease, Adult-Onset - therapy
Young adults
title Still’s Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Still%E2%80%99s%20Disease%20Onset%20in%20Older%20Adults:%20Clinical%20Features,%20Diagnosis,%20and%20Management&rft.jtitle=Drugs%20&%20aging&rft.au=Tada,%20Yoshifumi&rft.date=2024-09-01&rft.volume=41&rft.issue=9&rft.spage=713&rft.epage=724&rft.pages=713-724&rft.issn=1170-229X&rft.eissn=1179-1969&rft_id=info:doi/10.1007/s40266-024-01137-6&rft_dat=%3Cproquest_cross%3E3087699406%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3108815777&rft_id=info:pmid/39097535&rfr_iscdi=true